Regulation - Pricing

Filter

Current filters:

Pricing

Popular Filters

26 to 50 of 322 results

UK NICE consults on draft guidance for Gilead’s hepatitis C drug Sovaldi

UK NICE consults on draft guidance for Gilead’s hepatitis C drug Sovaldi

16-06-2014

In draft recommendations published today, UK health care watchdog the National Institute for Health and…

Anti-viralsBiotechnologyGilead SciencesPricingRegulationSovaldiUK

UK’s NICE says “Yes” to Bristol-Myers’ Yervoy

UK’s NICE says “Yes” to Bristol-Myers’ Yervoy

13-06-2014

People in England with advanced skin cancer should be able to receive ipilimumab as a first treatment…

Bristol-Myers SquibbOncologyPharmaceuticalPricingRegulationUKYervoy

French Transparency agency backs Gilead’s new hepatitis C drug Sovaldi

French Transparency agency backs Gilead’s new hepatitis C drug Sovaldi

09-06-2014

There was good news for US antivirals major Gilead Sciences, when France’s health technology assessment…

Anti-viralsBiotechnologyFranceGilead SciencesPricingRegulationSovaldi

Genzyme gains UK NICE backing for second MS drug Lemtrada

Genzyme gains UK NICE backing for second MS drug Lemtrada

28-05-2014

The UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has issued final guidance…

AubagioBiotechnologyGenzymeLemtradaNeurologicalPricingRegulationSanofiUK

NICE gives negative guidance on Janssen’s Stelara for psoriatic arthritis

NICE gives negative guidance on Janssen’s Stelara for psoriatic arthritis

28-05-2014

US health care giant Johnson & Johnson subsidiary Janssen today received a negative opinion from UK watchdog…

DermatologicalsInflammatory diseasesJanssenJohnson & JohnsonPharmaceuticalPricingRegulationStelaraUK

IQWIG finds added benefit in adult patients for VIIV Healthcare’s Tivicay

27-05-2014

In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products (AMNOG),…

Anti-viralsGermanyGlaxoSmithKlinePharmaceuticalPricingRegulationTivicayViiV Healthcare

NICE draft guidance negative on Celgene’s Revlimid

20-05-2014

UK health care cost watchdog the National Institute for Health and Care Excellence (NICE) has today issued…

BiotechnologyCelgeneOncologyPricingRegulationRevlimidUK

Negative IQWiG view on AstraZeneca’s combo diabetes drug Xigduo

16-05-2014

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

AstraZenecaDiabetesGermanyPharmaceuticalPricingRegulationXigduo

UK’s NICE backs Janssen’s Invokana for type 2 diabetes

16-05-2014

Janssen, a subsidiary of US health care giant Johnson & Johnson, said today that it welcomes the publication…

DiabetesInvokanaJanssenJohnson & JohnsonPharmaceuticalPricingRegulationUK

Negative NICE draft guidance on Janssen’s Zytiga for prostate cancer

Negative NICE draft guidance on Janssen’s Zytiga for prostate cancer

14-05-2014

In draft guidance published this morning, the UK drugs watchdog the National Institute for Health and…

JanssenJohnson & JohnsonOncologyPharmaceuticalPricingRegulationUKZytiga

Eisai expands deal with Biogen; re-files Fycompa with G-BA; news on Zebinix

Eisai expands deal with Biogen; re-files Fycompa with G-BA; news on Zebinix

12-05-2014

Japanese drug major Eisai has exercised its option to jointly develop and commercialize its clinical…

Biogen IdecEisaiFycompaGermanyItalyLicensingNeurologicalPharmaceuticalPricingRegulationZebinix

NICE issues positive recommendation for Astellas' Xtandi

NICE issues positive recommendation for Astellas' Xtandi

09-05-2014

In an about turn, UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has…

Astellas PharmaOncologyPharmaceuticalPricingRegulationUKXtandi

IQWiG finds added benefit for Novo Nordisk’s NovoEight not proven

23-04-2014

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

GermanyHematologyNorthern EuropeNovo NordiskNovoEightPharmaceuticalPricingRegulation

UK’s NICE rejects use of Roche’s Kadcyla for breast cancer on NHS

23-04-2014

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has today issued preliminary…

KadcylaNorthern EuropeOncologyPharmaceuticalPricingRegulationRocheUK

Ukraine pharma trade group APRaD sets out priorities with Vice PM and Customs authority

Ukraine pharma trade group APRaD sets out priorities with Vice PM and Customs authority

14-04-2014

The Ukraine Association of Pharmaceutical Research and Development (APRaD) participated in a meeting…

Eastern EuropePharmaceuticalPoliticsPricingRegulationUkraine

GSK’s Tafinlar also no added benefit over vemurafenib, says IQWiG

GSK’s Tafinlar also no added benefit over vemurafenib, says IQWiG

09-04-2014

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

GermanyGlaxoSmithKlineNorthern EuropeOncologyPharmaceuticalPricingRegulationTafinlarvemurafenib

UK’s NICE reverses negative decision on Roche’s Tarceva for NSCLC

04-04-2014

Following a consultation period, the UK drug watchdog the National Institute for Health and Care Excellence…

Northern EuropeOncologyPharmaceuticalPricingRegulationRocheTarcevaUK

Germany’s IQWiG views Xofigo, Kadcyla and Eviplera

03-04-2014

In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products, the…

Anti-viralsBayerEvipleraGermanyGilead SciencesKadcylaNorthern EuropeOncologyPharmaceuticalPricingRegulationRocheXofigo

UK’s NICE does not recommend Janssen’s Stelara for psoriatic arthritis

UK’s NICE does not recommend Janssen’s Stelara for psoriatic arthritis

28-03-2014

Final draft guidance from the UK health care costs watchdog the National Institute for Health and Care…

Anti-Arthritics/RheumaticsJanssenJohnson & JohnsonNorthern EuropePharmaceuticalPricingRegulationStelara InjectionUK

NICE final guidance again rejects Sanofi’s Zaltrap for colorectal cancer

25-03-2014

UK drugs watchdog the National Institute for Health and Care Excellence (NICE), today issued final guidance…

Northern EuropeOncologyPharmaceuticalPricingRegulationSanofiUKZaltrap

US lawmakers question price of Gilead’s Sovaldi

US lawmakers question price of Gilead’s Sovaldi

24-03-2014

Three leading US Congressmen have written to John Martin, chief executive of US biotech firm Gilead Sciences,…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaPoliticsPricingRegulationSovaldiUSA

UK’s NICE unable to give the go ahead to new prostate cancer drug Xofigo

24-03-2014

The UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has issued new draft…

BayerNorthern EuropeOncologyPharmaceuticalPricingRegulationUKXofigo

26 to 50 of 322 results

Back to top